Tamara Davenne holds a master’s degree in molecular and cellular biology (Université Libre de Bruxelles) and did her PhD in Infection, Immunology and Translational Medicine (Wellcome Trust studentship) under the supervision of Prof. Jan Rehwinkel at the Weatherall Institute of Molecular Medicine (Oxford University 2014-2018). She then did a postdoc at the KU Leuven (Belgium) working on T cell lymphoblastic leukaemia in the lab of Prof. Kim De Keersmaeker before joining InhaTarget Therapeutics as principal scientist in 2020.
Expert in immuno-oncology, she is particularly interested in developing strategies harnessing the immune system to fight cancer and thus her interest overlapped with InhaTarget’s. Together with formulation specialists she works with, the team develops innovative formulations for pulmonary drug delivery to enhance lung cancer treatment. Tamara is managing in vitro and in vivo preclinical activities. The most exciting part of her role is the possibility to transform ideas into formulation, thanks to the complementary formulation expertise in the team, and to develop these novel formulations to reach clinical trial in order to improve lung cancer treatment efficacy